28 Day Randomized Double-Blind Placebo Controlled Trial using Pre-Polymerized Cross-Linked Sucralfate Barrier (Esolgafate) for Erosive GERD
Abstract
Background: Treatment of erosive gastroesophageal reflux disease (eGERD) centers on control of acid pH using proton pump inhibitors (PPI), histamine 2 receptor antagonists (H2RA) and antacids (AA). However, the presence of bile and serine proteases in gastric refluxate, not addressed by PPI, H2RA or AA, is suspected to be associated with onset of Barrett’s esophagus and rise of esophageal adenocarcinoma. Pre-polymerized sucralfate barrier therapy (PPSBT) recognized first by US FDA as a medical device has enhanced bio adherence and blocks access of acid and non-acid irritants to the mucosa. Aim: To evaluate the efficacy of mucosal protection by PPSBT for the treatment of erosive GERD. Methods: In a 28 day statistically powered, multi-center randomized double-blind placebo controlled trial, 19 patients with eGERD were randomized to receive PPSBT or placebo. Antacids were available to each group for breakthrough pain. Treatment effect on erosions and eGERD symptoms (heartburn & reflux sensation) were evaluated. Adverse events were assessed. Results: For patients taking PPSBT, 89% and 78% had relief of heartburn and reflux respectively compared to 25% and 12.5 % of those on placebo. Complete healing occurred in 89% taking PPSBT compared to 25% of those on placebo. No adverse events occurred. Conclusions: Enhanced mucosal protection by PPSBT demonstrates effective symptom control and erosion healing in patients with eGERD. Acid-indifferent cytoprotection from acid, bile and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.